CVR 33956509Private limited company (ApS)Anden finansiel formidling undtagen forsikring og pensionsforsikring, i.a.n. (649900)Vassingerødvej 9, 3540 LyngeFounded 3 Oct 2011
Compare withsimilar companiesanother companyits industry
GIN INVEST I ApS
CVR holds no employment figures for this company.
The newest trades with a company on a side are on the latest property trades.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Cite as: GIN INVEST I ApS, https://dandex.ai/company/33956509/gin-invest-i. Source: Dandex, from CVR, read 22 Nov 2026.
Dandex is Danish Company Data. Connect it once and ask about GIN INVEST I ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Dandex has an MCP server at https://dandex.ai/mcp and a REST API at https://dandex.ai/api/v1.
Set up DandexResult
+914.7K
DKK, annual report 2023
Equity
4.4M
DKK, annual report 2023
MISSIONPHARMA GROUP ApSCVR 29782792, 100% of capital and votes, until 15 Dec 2023
Christian Monrad Overgaarduntil 15 Dec 2023
Alexandre Pierre Jean Vialatteuntil 15 Dec 2023
No current owner is registered.
CVR 29782792100% of capital and votes5 Oct 2011 to 15 Dec 2023
CVR lists no current officers for this company.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2023, DKK: Operating profit -30.3K, Result for the year 914.7K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2023, DKK: Total assets 4.5M, Equity 4.4M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Gross profit | -10 | Not reported | Not reported | Not reported | Not reported |
| Operating profit | -10 | -10 | -11 | -11 | -30 |
| Result for the year | +797 | +1,127 | +946 | +933 | +915 |
| Equity | 4,156 | 4,872 | 5,585 | 6,558 | 4,447 |
| Total assets | 5,766 | 6,492 | 7,215 | 6,578 | 4,496 |
Annual report 2023
1 Apr 2022 to 31 Mar 2023, published 6 Jul 2023
Annual report 2022
1 Apr 2021 to 31 Mar 2022, published 8 Jul 2022
Annual report 2021
1 Apr 2020 to 31 Mar 2021, published 15 Jul 2021
Annual report 2020
1 Apr 2019 to 31 Mar 2020, published 7 Jul 2020
Annual report 2019
1 Apr 2018 to 31 Mar 2019, published 10 Jul 2019
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| FoundingCashPaid in 100,000 | None | 100,000 | None | 100,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
The company's own figures, in DKK, from the annual reports filed in XBRL.
| DKK thousands | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Merger (fusion), as the ceasing company (ophørende selskab)
Source: CVR, read 22 Nov 2026.
19 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående fusion.
Virksomheden er d. 15.12.2023 opløst ved fusion med CVR-nummer: 26902398 MISSIONPHARMA A/S.
Erhvervsstyrelsen har modtaget fusionsplan for den påtænkte fusion mellem CVR-nummer: 26902398 MISSIONPHARMA A/S (fortsættende), der tillige driver virksomhed under navnene MISSIONPHARMA INTERNATIONAL PROJECT SERVICES A/S, MISSIONPHARMA INTERNATIONAL RELIEF SERVICES A/S, MISSIONPHARMA INTERNATIONAL A/S, INTERNATIONAL PROJECT SERVICES A/S, Missionpharma Properties A/S, Missionpharma Ejendomme A/S og CVR-nummer: 33956509 GIN INVEST I ApS (ophørende).
Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i CVR-nummer: 26902398 MISSIONPHARMA A/S og CVR-nummer: 33956509 GIN INVEST I ApS må antages at være tilstrækkeligt sikrede efter fusionen.
Bestyrelse:
Fratrådte:
Aymeric Erouart, den 01.02.2023.
Revision:
Fratrådte:
PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB, den 29.06.2022.
Tiltrådte:
CVR-NR. 31061741 MAZARS STATSAUTORISERET REVISIONSPARTNERSELSKAB, Midtermolen 1, 2. tv, 2100 København Ø, den 29.06.2022.
Direktion:
Fratrådte:
Poul Lindof, den 30.11.2021.
Bestyrelse:
Fratrådte:
Annie Renée Simonne Dateu, den 03.12.2020.
Tiltrådte:
Patricia Hec, den 03.12.2020.
Vedtægter ændret: 13.02.2019
Bestyrelse:
Fratrådte:
Kim Erik Ginnerup, den 13.02.2019.
Tiltrådte:
Kim Erik Ginnerup, (næstformand), den 13.02.2019, Annie Renée Simonne Dateu, den 13.02.2019, Aymeric Erouart, den 13.02.2019.
Selskabet tegnes af to bestyrelsesmedlemmer i forening, eller af to direktører i forening, eller af den samlede bestyrelse.
Direktion:
Fratrådte:
Kim Erik Ginnerup (adm. dir), den 30.08.2018.
Tiltrådte:
Christian Monrad Overgaard (adm. dir), den 30.08.2018.
Vedtægter ændret: 06.12.2017
Regnskabsår ændret til: 01.04 - 31.03
Omlægningsperiode: 01.01.2018 - 31.03.2018
CVR-nummer
33956509.
NAVN:
GIN INVEST I ApS.
Adresse: Vassingerødvej 9, 3540 Lynge.
Kommune: Allerød.
Revision:
Fratrådte:
KPMG STATSAUTORISERET REVISIONSPARTNERSELSKAB, den 20.04.2015.
Tiltrådte:
CVR-NR. 33771231 PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB, Strandvejen 44, 2900 Hellerup, den 20.04.2015.
Direktion:
Udtrådt af direktionen:
Mikkel Mørkedal Wakefield, den 15.03.2013.
Indtrådt i direktionen:
Direktør Kim Erik Ginnerup (adm. dir), den 15.03.2013.
Direktion:
Fratrådt som adm. dir tiltrådt som Økonomidirektør: Poul Lindof, den 30.11.2012.
Indtrådt i direktionen:
Mikkel Mørkedal Wakefield (adm. dir), den 30.11.2012.
Vedtægter ændret:
20.11.2012.
Revision:
Udtrådt af revisionen:
CVR-NR. 26052394 ERNST & YOUNG P/S, den 20.11.2012.
Indtrådt i revisionen:
CVR-NR. 30700228 KPMG STATSAUTORISERET REVISIONSPARTNERSELSKAB, Osvald Helmuths Vej 4, postboks 250, 2000 Frederiksberg, den 20.11.2012.
Regnskabsår ændret til:
01.01 - 31.12.
Omlægningsperiode:
01.05.2012 - 31.12.2012.
Vedtægter ændret:
01.11.2012.
Bestyrelse:
Indtrådt i bestyrelsen:
Jean-Marc Pierre Rene Leccia (formand), den 01.11.2012, Denis Georges Fernand Maurice (næstformand), den 01.11.2012, Direktør Kim Erik Ginnerup, den 01.11.2012, Eric Pierre Jean Muris, den 01.11.2012.
Selskabet tegnes af to bestyrelsesmedlemmer i forening, af tre direktører i forening, af næstformanden for bestyrelsen i forening med en direktør eller af den samlede bestyrelse.
Stiftelsesdato:
03.10.2011.
Seneste vedtægtsdato:
03.10.2011.
Kapital:
kr. 100.000,00.
Indbetalingsmåde:
Indbetalt kontant kr. 100.000,00 til kurs 100,00.
Stifter:
CVR-NR. 29782792 MIFAMED HOLDING ApS, Langelinie Allé 7, 2100 København Ø, den 03.10.2011.
Direktion:
Direktør Poul Lindof (adm. dir), den 03.10.2011.
Selskabet tegnes af en direktør.
Revision:
CVR-NR. 26052394 ERNST & YOUNG P/S, Gyngemose Parkvej 50, 2860 Søborg, den 03.10.2011.
Første regnskabsår:
03.10.2011 - 30.04.2012.
Regnskabsår:
01.05 - 30.04.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 22 Nov 2026.
What Pro holds for GIN INVEST I ApS:
Have Pro? Sign in.
P-number 1017164224Vassingerødvej 9, 3540 Lynge